Observational studyClinical and experimental nephrology2026
Erythropoiesis-stimulating agent resistance is associated with diabetic kidney disease but not with diabetes: a post hoc analysis of the BRIGHTEN study.
Observational study in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErythropoiesis-stimulating agent (ESA) resistance in chronic kidney disease (CKD) is influenced by various factors, including diabetes. Although diabetes has been linked to ESA resistance, the BRIGHTEN study in Japan found no direct correlation. This study aimed to identify factors contributing to ESA resistance in patients with diabetes by analyzing the diabetic kidney disease (DKD) status and CKD stage.
methodsA post hoc analysis was conducted using data from the BRIGHTEN study, a multicenter prospective observational trial investigating ESA resistance in patients with non-dialysis-dependent CKD. Patients were categorized based on diabetes status (DM vs. non-DM) and further stratified by CKD stage and presence of DKD. ESA resistance was assessed using the erythropoietin resistance index.
resultsNo significant differences in ESA resistance were observed between the DM and non-DM groups. However, among patients with diabetes, those with DKD exhibited higher ESA resistance and required higher darbepoetin alfa (DA) dosages than did those with non-DKD nephropathy (NDKD-DM). ESA resistance and DA dosage increased with CKD progression, with notable differences in CKD stage G4 between the DKD and NDKD-DM groups.
conclusionAlthough diabetes alone was not associated with ESA resistance, patients with DKD exhibited higher resistance, suggesting that ESA resistance is more closely linked to DKD than to diabetes itself. These findings highlight the role of proteinuria and inflammation in the ESA response, emphasizing the need for individualized anemia management strategies based on nephropathy type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.